ROS1 and neoplasm: Having ascertained that thedegrader molecules areorally bioavailablein rats, we next conducted in vivo efficacy studies by oral administrationof 9o in NOD/SCID mice bearing ROS1-dependent Ba/F3 xenografts.In the CD74-ROS1 xenograft (Figure 5A), as expected, crizotinib was modestly effectivein inhibiting tumor growth, achieving 35% tumor growth inhibition(TGI).